8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): February 23, 2007

                         Renhuang Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)

                                     Nevada
                 (State or Other Jurisdiction of Incorporation)


                  0-24512                          88-1273503
          (Commission File Number)    (IRS Employer Identification Number)

                    No. 281, Taiping Road, Taiping District,
                      Harbin, Heilongjiang Province, 150050
                                   P. R. China
                    (Address of Principal Executive Offices)

                                +86-451-5762-0378
              (Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


- --------------------------------------------------------------------------------





Item 7.01   Regulation FD Disclosure.

     On February 23, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued
a press release, a copy of which is attached as Exhibit 99.1 to this report and
is being furnished to the SEC and shall not be deemed "filed" for any purpose.


Item 9.01   Financial Statements, Pro Form Financial Information and Exhibits.

(c)         Exhibits.


                                    EXHIBITS

Exhibit              Description
- -------              ----------------------------------------------
99.1                 Press Release dated February 23, 2007.


- --------------------------------------------------------------------------------







                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     Renhuang Pharmaceuticals, Inc.


Date: February 23, 2007              By: /s/ Shaoming Li
                                         ---------------------------------------
                                         Shaoming Li
                                         Chief Executive Officer and President


- --------------------------------------------------------------------------------

EX-99.1

                                                                    Exhibit 99.1


Renhuang Pharmaceuticals Files Amended 10K/A for the Six Month Transition Period
May 1 - October 31, 2006: Revenues Up and Net Income Grew Significantly Year
over Year


    Highlights:

    --  Restated net income of $4.23 million more than doubled compared to the
        net income of $1.77 million for the same period of the prior year

    --  Revenues of $12.25 million up 24% compared to the restated revenues of
        $9.90 million for the same period of the previous year

    --  Earnings per share for the current six month period restated as $ 0.121


    HARBIN, China--(BUSINESS WIRE)--Feb. 23, 2007--Renhuang Pharmaceuticals,
Inc. (or "the Company", Stock symbol: RHGP.OB), a leading provider of natural
health care products in the People's Republic of China (PRC), filed an amended
10K yesterday for the transition period of May 1 to October 31, 2006 (which is
the second half of the Company's 2006 fiscal year). On February 13, 2007, the
Company filed its first 10K since it became a public company in the U.S. in
September 2006. Amended 10K filed yesterday mainly reflects additional general
and administrative expenses and reclassifies sales rebates as a reduction from
sales instead of as a selling expense for the 2005 period. None of the changes
materially affected the earnings and earnings comparison. The table below
reflects the major changes. A detailed explanation is available in the Company's
current report 10K/A dated and filed with the Securities and Exchange Commission
on February 22, 2007.

    Key Figures


                         May 1 - Oct. 31          May 1 - Oct. 31
                              2006                      2005
- ----------------------------------------------------------------------
                      Restated     Original    Restated     Original
======================================================================
Revenue             $12,247,489  $12,247,489  $9,898,073  $11,721,151
- ----------------------------------------------------------------------
Net Income          $4,225,214   $4,404,578   $1,768,776  $1,768,776
- ----------------------------------------------------------------------
Net Profit Margin        35%          36%         18%          15%
- ----------------------------------------------------------------------

                         YoY% Change
- --------------------------------------------
                    Restated      Original
============================================
Revenue                24%           4%
- --------------------------------------------
Net Income            139%          149%
- --------------------------------------------
Net Profit Margin
- --------------------------------------------


    The revisions resulted in a decrease of $1.82 million in revenues for the
prior year six month period from May 1 to October 31, 2005. The restated
revenues for the prior year period reflect changes made to be consistent in the
way that revenues and sales commissions are recorded according to the U.S. GAAP.
The revisions also resulted in lower selling and distribution expenses and
higher other expenses for the same period due to reclassification of certain
expenses. There were no changes to the previously announced revenues for the
current six month period.

    With the amendment, revenues of $12.25 million for the current six month
period from May 1 to October 31, 2006 actually grew 24% compared to the restated
revenues of $9.90 million for the same period of last year. The year over year
growth of sales was attributable to the continued market growth due to strong
demand for all product lines that the Company offers, including Acanthopanax
medical products, Shark Power Health Care products, and Traditional Medical
products, which respectively contributed 53%, 12%, and 35% to the total
revenues.

    The net income for the current six month period ending October 31, 2006 was
restated as $4.23 million from the previously announced $4.40 million. The
slight decrease of net income for the current period was due to certain
additional administrative expense that was not reflected previously. There were
no changes to the previously announced net income for the prior year period.
This revision did not affect the earnings and earnings comparison materially.

    Therefore, the restated net income of $4.23 million for the current six
month period increased 139% compared to the $1.77 million net income for the
same period last year. The substantial year-over-year growth of earnings was
primarily driven by higher sales, lower operating expenses, and some financial
restructuring related to the reverse merger.

    Basic earnings per common share for the six month period were restated as
$0.121 per share versus the $0.125 per share previously.

    Given the fact that the six months ended October 31, 2006 was the Company's
first reporting period and the Company only conducted the current operations
from May 1, 2006 through October 31, 2006, a financial projection based only on
the current and the prior year results may not be a good indication of the
Company's future performance. Due to seasonality, current six month revenues of
$12.25 million may not be indicative of the revenues in future periods. The
financial comparison and projection will be more indicative after the Company
has conducted its current operations for a few more periods.

    Commenting on the revisions, Renhuang's Chairman Mr. Li, Shaoming said, "As
a young public company in the U.S., we have been working hard in adapting our
accounting standards to the U.S. GAAP with the help of our auditor. The
amendments we made today were mainly due to technicalities. In the past, sales
and sales commissions were recorded at different times and the commissions were
booked as expenses. To ensure that our past results are consistent with the
future results and with the U.S. GAAP, the sales commissions are now booked as
offsetting sales. This change resulted in the revision to the revenues recorded
for the six month period in 2005."

    Outlook

    The Company remains very optimistic about growing its earnings and revenues
over time. Driven by fast growing economy in China, higher disposable income per
capita, increased attention to health, and favorable government policy towards
improving quality of life, the Company is positioned to grow continuously. The
Company anticipates more new products to be approved by SFDA (Chinese State Food
& Drug Administration) and to be launched in the coming years. The Company also
expects to expand its market internationally as consumers around the world are
seeking alternative medicines and as Renhuang's products are increasingly sought
after due to growing awareness of the efficacy of natural health care products
and Chinese herbal medicine.

    Mr. Li, Shaoming added, "I would like to stress that the Company delivered
strong results for its first six month period as a public company. Our sales
continued to grow year over year in each of our major product lines and our
earnings more than doubled from the same period of last year. With our highly
sought after products, strong R&D program, superior manufacturing capability,
and large distribution network, we believe we are capable of delivering
consistent growth to our shareholders. We reiterate our expectations for the
fiscal year 2007 with revenues in the range of $ 35 to $ 40 million and net
profits in the range of $ 10 to $ 12 million."

    Details of the Company's amended financial data for the transition period
from May 1 - October 31, 2006 are available in the Company's amended Current
Report 10K/A dated and filed with the Securities and Exchange Commission on
February 22, 2007.

    About Renhuang Pharmaceuticals, Inc.:

    Renhuang Pharmaceuticals is a leading bio-pharmaceutical company located in
Harbin in the Heilongjiang Province in Northeast China. Renhuang is primarily
engaged in the research, production, and sales of bio-pharmaceutical products in
Mainland China. The Company's main products are Siberian ginseng, shark liver
oil and several other traditional medical products. It is estimated that 70% of
China's natural supply of Siberian Ginseng is currently controlled by the
Company.

    The company also anticipates approval within six to nine months by State
Food and Drug Administration ("SFDA") for up to five of its new Monoclonal
Antibody Reagent Box series products. These products are 60% more reliable than
those from its competitors and also adhere to "Good Manufacturing Practices", or
"GMP". Moreover, the company is in the process of building its own immune system
research and development function. Overall, the company is able to achieve
significant cost savings compared to most of its competitors, who purchase their
raw materials from third parties.

    Over 2000 sales agents are employed in seventy sales centers across
twenty-four districts and cover over 50% of the greater China area and 80% of
its population, including the most populous and developed Eastern China. The
Company employs over 50 people in its R&D department, a number of which are well
recognized and respected pharmaceutical professors and research scientists from
National Navy Pharmaceutical Research Center, Beijing Ellionbio Research Center
and other well known institutions. State of the art research and production
facilities using the latest technologies are currently used by the Company's
scientists to develop new and innovative areas, including antiseptic and immune
system products and Diagnostic kits.
RHGP-G

    Safe Harbor Statement

    This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933, and the
Securities Exchange Act of 1934. All statements, other than statements of
historical facts, included herein are 'forward-looking statements.' Although the
Company believes that the expectations reflected in these forward-looking
statements are reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. You should not place undue
reliance on these forward-looking statements, which speak only as of the date of
this press release.

    The Company's actual results could differ materially from those anticipated
in these forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that are filed with
and available from the Securities and Exchange Commission. All forward-looking
statements attributable to the Company or persons acting on its behalf are
expressly qualified in their entirety by these factors. Other than as required
under the securities laws, the Company does not assume a duty to update these
forward-looking statements.

    CONTACT: Christensen
             Christy Shue, 917-576-2209
             cshue@ChristensenIR.com
             or
             In China:
             Renhuang Pharmaceuticals Inc
             Gina Gao, 0086-451-57620378
             Fax: 0086-451-57606414
             gs@renhuang.com